R. Castellano

Downregulation of stromal syntenin sustains AML development

This study shows that reduced stromal syntenin in bone marrow stromal cells promotes AML aggressiveness by enhancing AML cell survival and protein synthesis through endoglin upregulation.

DOK1 and DOK2 regulate CD8+ T cell signaling and memory formation without affecting tumor cell killing

This study shows that DOK1 and DOK2 inhibit CD8+ T cell memory formation but not tumor cell killing, enhancing TCR signaling without improving cytotoxicity.

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

This study shows that deleting CISH enhances NK cell activation and anti-tumor responses in both mice and human cells, suggesting CISH as a therapeutic target for improving NK cell immunotherapy.

A syntenin-deficient microenvironment educates AML for aggressiveness

This study shows that syntenin-deficiency in the bone marrow microenvironment promotes AML aggressiveness by enhancing cell survival through autophagy and protein synthesis.

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance

This study develops a mouse model of TNBC that recapitulates human tumor heterogeneity and identifies a synergistic combination of WEE1 and BCL-XL inhibition as a potential treatment.

Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator

This study identifies DDAs as compounds that upregulate DR5 in cancer cells, leading to apoptosis and synergy with TRAIL, with selectivity for oncogene-transformed cells.